You’ve probably heard stories like this before. A 34-year-old software developer in Bangalore. He weighs less than average. He runs three times per week. After an Annual visit to his physician, he receives a report which shows that his BP is fine; his LDL Cholesterol is borderline acceptable, and his fasting glucose is at 98 mg/dl. His Doctor advises him to continue with what he’s doing. Two years after receiving that advice, he is told that he now has type II diabetes mellitus. Throughout those two years, his BMI was always at 22.4.
Stories such as these are becoming commonplace. In fact, there is a medical term for the description above. “Metabolically Obese normal weight,” (or mono) refers to persons with a normal body-mass-index (BMI), however, whose metabolism mirrors that of a morbidly obese individual, excessive intra-abdominal adiposity, insulin resistance, dyslipidemia, and chronic low-level systemic inflammation, are completely masked on a standard scale and are often undetectable using the standard blood test commonly used by primary care physicians.
In fact, the National ICMR-India Study 2025, which represents the largest population-based study of metabolism in the country of India, involving over one million indians, reported that approximately 43.3% of adult indians meet criteria for being classified under the mono category. Therefore, nearly half of all individuals with a normal BMI and clean-looking laboratory results have some level of metabolic compromise. Individuals who are metabolically impaired cannot be identified unless testing specifically directed toward identifying metabolic impairment is performed. Such patients do not exhibit any obvious physical signs associated with obesity.
That is the fundamental flaw.
Physicians generally use the same basic tools today to assess patient health status: BMI measurement, routine fasting glucose assessment, and basic lipid profiles. None of these tests was intended to identify normal-weight obesity; rather, they were developed as general population screening tools to identify potential metabolic problems. As such, when your physician tells you your weight is in a healthy range, and therefore so too should your metabolic health, the data increasingly suggests otherwise.
According to recent data studies, more than 40 percent of new-onset type II diabetic patients among asian populations present with a BMI < 22 kg/m². This is not due to a lack of commitment to maintaining good health practices. Many of these patients had been compliant with all of the traditional recommendations. The issue lies with how we define compliance. We need to recognize that our current methods for assessing patient compliance to maintain optimal health are not valid, and, if we want to begin making progress toward reducing disease prevalence among normal-weight individuals, we need to start redefining what defines success.
Adolphe Quetelet, a Belgian Mathematician, astronomer, and statistician, created the Quetelet index (which would later be renamed body mass index) in 1832 to describe the statistically average male. Neither Quetelet nor Ancel Keys, WHO coined the term “body mass index” in 1972, was a doctor. Keys used data from a sample of about 7,400 “normal men”, which consisted completely of non-Hispanic white males exclusively. Thus, this group did not represent the South Asian, African, or women groups. Brief lands amen clinics
It is not a minor footnote. This is a basic flaw that defines how we practice medicine today, and now, this flaw is being officially dismantled.
January 2025 saw the publication of The Lancet Diabetes & Endocrinology’s landmark Commission on clinical obesity, a framework put together by 58 international experts, and endorsed by 76 medical organizations worldwide, officially declaring that BMI cannot be relied upon as a measure of health or disease at the Patient level. The Commission’s findings were clear: waist circumference, waist-to-height ratio, and direct fat measurement must supplement or replace BMI when making a medical diagnosis of obesity. People with excess fat do not always have a BMI indicating they are obese. As such, their health problems are frequently missed. Kentiri bw wellbeing world.
Indian bodies experience the failure of BMI more so than any other population group. Studies that validated BMI cutoff levels for Western populations documented much higher rates of cardiometabolic abnormalities among indian study participants at identical BMI levels. Therefore, the World Health Organization lowered its overweight/obesity thresholds specifically for asian populations. A number that clears a European does not constitute a clinical clearance for an indian. The BMI myth is not a fringe argument. Rather, the position of the world’s most prestigious medical journals directly explains why normal weight but a high percentage of body fat is so often missed by consulting rooms in India. Frontiers
India’s growing number of diabetic individuals are consistently told they got diabetes due to their “poor eating” or “sedentary behavior”. The problem is that this explanation does not tell the whole story. For millions of Indians who suffer from diabetes, there is damage being done by this quiet narrative.
At the same BMI as Europeans, South Asians will typically have less lean muscle mass but more overall body fat, particularly visceral (around the stomach) and abdominal fat. More importantly, abdominal fat produces more inflammation when broken down than visceral fat does in other ethnic groups. This has nothing to do with lifestyle choices. This is a proven physiological characteristic of South Asian descent that can lead to severe medical complications. (PubMed Central)
The 2025 American Diabetes Association study on the Gujarat Phenotype provided a basis for understanding these trends through empirical data. Of the over 1500 adults surveyed with normal BMI, nearly half of those surveyed exhibited the thin-fat Indian phenotype via having excessive amounts of body fat and visceral fat. In addition to carrying significant amounts of body fat and visceral fat, almost all of them (50%) also demonstrated fasting blood sugar that was elevated; roughly two-thirds (66.7%) demonstrated increased HOMA-IR, which is directly related to insulin resistance, and about one-third (33.3%) had elevated HbA1c. Thin. Abnormally functioning metabolism. (Frontiers)
South Asians inherently possess a smaller capacity to store fat within their subcutaneous tissues. Genetic testing in India is now revealing the specific gene variants, including FTO, TCF7L2, and PPARG polymorphisms, that predispose South Asians to ectopic fat deposition and insulin resistance at lower body weights, validating what population studies have long observed. As such, if they consume too many calories, then that excess energy will spill into ectopic locations (such as the liver, pancreas, heart, etc.), causing metabolic problems at body weights that would produce no adverse effects in a European patient. (Nature)
That is why thin Indians get diabetes at higher rates than expected using traditional Western clinical standards. While metabolic syndrome with normal BMI may be seen in some parts of the world, it is not an aberration in India. The fact remains that metabolic syndrome with normal BMI is a fundamental structural physiological phenomenon in India, and standard diagnostic screenings were never created to diagnose this issue.
In addition to being inaccurate, blaming lifestyle choice alone also creates barriers to Indians receiving the proper testing.
MONO does not advertise its presence. Rather than announcing itself as an overweight condition or being visible on the scale, MONO has a silent biological process that starts in the visceral fat (the internal layer of abdominal fat) and can lead to organ damage.
When visceral fat secretes pro-inflammatory cytokines such as TNF-α, IL-6, and MCP-1 into the bloodstream, they cause systemic inflammation and interfere with metabolic functions. In addition, these cytokines damage the signaling pathways for insulin receptors. Specifically, TNF-α prevents the signaling pathway of the insulin receptor substrate, which is essential for cells to take up glucose. As a result, the ability of the cell to use glucose decreases; this is called accelerated insulin resistance. There is nothing “obesity” related about the inflammatory response of visceral fat. The visceral fat uses specific molecular mechanisms to intentionally destroy the metabolism of a person who has a body mass index (BMI), and/or actual weight, that would never warn anyone of an impending health crisis. Skinesa
First in line is the liver. The excess free fatty acids secreted by the visceral fat pour into the portal vein and create hepatic insulin resistance. Hepatic insulin resistance creates Non-Alcoholic Fatty Liver Disease (NAFLD). NAFLD will often develop before there are even abnormal readings of blood sugar levels. Next is the pancreas. The persistent exposure to inflammatory cytokines causes apoptosis (death) of pancreatic beta-cells. This death reduces the number of functioning beta-cells in the pancreas and thus diminishes its ability to produce insulin. Over time, this will exhaust the pancreas’s ability to make insulin. Skinesa
According to ICMR-INDIAB 2025, persons identified with MONO have a significantly increased risk of Type II Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD), and Chronic Kidney Disease (CKD); all three are among India’s most common causes of premature deaths. T2DM, CAD, and CKD can develop while their BMI and/or actual weight remain within what is considered normal. A physician may also reassure them that, based upon standard measurements, their physical health appears to be perfectly fine. Frontiers
This is what “hidden obesity” in persons who are at a normal weight actually represents at the cellular level. The damage that occurs due to MONO is not theoretical; it is real. It is incremental. And, to a large extent, it is preventable – if detected early enough.
As part of a standard, yearly medical examination, most Indians undergo various blood tests to measure their fasting plasma glucose (FPG), hemoglobin A1c (HBA1C) levels, lipid profile (lipid panel), and liver enzyme levels. However, for an individual who falls into the MONO category, all of these examinations will likely yield completely normal results. At the same time, that person may be experiencing increasing amounts of visceral fat accumulation along with worsening insulin resistance. The issue is not with the accuracy of these exams; it is merely a matter of which measures are used to assess health status.
To diagnose correctly, a vastly different set of metabolic biomarkers needs to be measured, ones that standard panels were never designed to include: the TyG Index, or Triglyceride Glucose Index, has recently been identified as a more accurate and cost-effective method of determining insulin resistance in non-obese individuals, using a fasting plasma glucose and triglyceride measurement. Additionally, according to research studies referenced within this document, a MONO individual would be found to have a greater than two-fold increased likelihood of developing diabetes based on the use of TyG cut-off values. Like HOMA-IR, the TyG Index only requires a standard fasting blood sample. Neither the TyG nor HOMA-IR indexes are ever included in any routine health screenings in India.
As indicated above, Body Composition Measurement is another key deficiency in current assessments of cardiometabolic risks. Specifically, Visceral Fat Area, as determined by body composition assessment, is a far better predictor of cardiometabolic risks than BMI. Consequently, despite its proven superiority, body composition analysis via either InBody Scanning or DEXA is rarely, if ever, incorporated into virtually all routine health screenings throughout India. PubMed Central
Specifically, you should ask your doctor for:
Collectively, these tests form the foundation of a genuine metabolic and heart health checkup – one that screens accurately for visceral fat and elevated body fat percentage in normal-weight individuals, years before standard panels show any abnormal
These tests exist. These tests are relatively inexpensive. These tests are just not routinely ordered.
This is the section the wellness industry doesn’t want to acknowledge.
A majority of skinny-fat individuals report consuming “healthy” foods as defined by their diet plans, working out regularly, and being successful at work. They may also be getting 6 hours of sleep each night. Each component individually seems like a good thing to do. However, when they are all done together, they can actually cause (or continue) your body’s Mono condition.
The enzymes in Visceral Fat Tissue convert Cortisone into Active Cortisol on site. Essentially, it manufactures its own supply of active Cortisol. Thereby creating a loop in which Visceral Fat is the recipient and contributor to the same hormones that drive continued accumulation of Visceral Fat. Even chronic workplace stress alone, without a single change to the individual’s diet, can cause this loop. PubMed
Central Sleep is the second invisible lever. Restricting sleep for just 21 days caused an 11% increase in Abdominal Visceral Adipose Tissue (in healthy young adults). Although the individuals’ overall weights were essentially unchanged, their visceral fat was increasing. The scale wasn’t moving; however, the visceral fat was growing. nih
Exercise using aerobic methods, especially when used in conjunction with little to no strength training, has negative effects. While cardio burns calories, it does nothing to combat the Sarcopenic Obesity Pattern – characterized by low muscle mass with excessive amounts of visceral fat. As many Indians experience, this is exactly how they develop their specific MONO Phenotype. Stress from any source causes glucocorticoid signaling to activate and increases Visceral Fat regardless of calorie intake. PubMed
Reversing mono doesn’t have anything to do with losing weight. It’s about changing what your body is made of and how your body reacts to insulin. This is NOT the same objective, and this is why all interventions tend to fall apart when they’re mixed up.
Cardio vs. strength training. Strength training reduces visceral fat (including abdominal fat), improves insulin sensitivity, and improves glucose tolerance – regardless of your overall body weight. Glucose metabolism occurs primarily in skeletal muscle; therefore, building it will directly address the central metabolic flaw in mono. There is evidence-based minimum of three times/week strength training that includes progressive loads. Frontiers
What you eat matters way more than cutting calories. A Mediterranean Diet (vegetables, whole grain products, legumes, nuts, and olive oil) consistently demonstrates improvements in insulin resistance, triglycerides, fasting glucose, and abdominal obesity in the largest-scale studies. As such, for bodies from India, there should be no question on how to translate this principle: high protein intake, low refined carbohydrate load, high fiber content, and consumption of traditional fermented foods. Frontiers
Sleep can be considered a metabolic intervention. In order to manage mono, seven to nine hours of continuous sleep is not discretionary. Since the visceral fat-cortisol cycle outlined in section 6 is present in the population at risk of developing mono, sleep deprivation will undermine every single other treatment strategy being used simultaneously.
The honest disclaimer: combined treatments of diet and exercise produce greater reductions in visceral fat area than diet alone – but neither will produce a result if not performed consistently. There is no single regimen that works for everyone; therefore, personalized testing of metabolism will provide the best information on how to reverse mono without weight loss.
The mono diagnosis is not a personal failure. It’s a systems failure, a failure of the tools that medicine has relied on for almost two centuries to accurately measure what is actually happening inside Indian bodies.
More than 43% of the adult population of India is made up of mono individuals who are at an elevated risk of developing type 2 diabetes, coronary artery disease, and chronic kidney disease. But they can only be detected through targeted screening tests specific to them. There is no denial about this science, the gap exists entirely in detection. Frontiers
To close that gap, we need to approach from a different point. Not the scales. Not annual checkups. But metabolic health assessment, which actually measures what really matters – fasting insulin, HOMA-IR, TyG index, body composition, visceral fat area, and inflammatory markers. These numbers will tell you the real story behind your normal BMI.
This is exactly what Longeny was built to address. Longeny’s MONO Panel & metabolic health plan, advanced metabolic screening (insulin resistance markers; body composition analysis; inflammatory biomarkers) with a personalized protocol by doctors, nutritionists, and health coaches working together. The approach doesn’t stop at the diagnosis. It translates results into a 90-day repair plan based on your biology, tracked weekly and adjusted as your markers improve.
Normal weight obesity is not a life sentence. It is the starting line for the right intervention. The tests exist. The evidence exists. The only remaining question is whether you know what to measure and if someone qualified is helping you take action.
Metabolically Obese Normal Weight (MONW) is when you have a “normal” weight by your Body Mass Index (BMI), but you have all the metabolic problems of being obese. That means you have too much visceral (around your organs) fat; you are resistant to insulin; your lipid profiles may be abnormal; and you have a low-grade systemic inflammatory process. Systematic reviews and meta-analyses of data worldwide estimated that about 26.78% of people with a normal BMI have at least one metabolic problem indicative of having an Obesity Phenotype for Metabolically Obese Normal Weight (MONW). Furthermore, this percentage appears to be higher in South Asians.
The primary way to identify MONW is NOT with a scale or standard blood work. Fasting insulin levels, Homeostasis Model Assessment of Insulin Resistance (HOMAIR), TyG index, and body composition measurements need to be obtained. These are tests that are seldom ordered as part of a routine yearly check. PubMed Central
Yes, and that’s why MONO has such potential danger when used clinically. A significant number of people with MONO are characterized as having either an increase in fat content, central (visceral) deposition of fat, or both, which means they will be experiencing many of the adverse metabolic effects associated with being overweight; but since their BMI is within the “normal” range, they will likely fall outside of standard screening criteria. This phenomenon is especially prevalent in India, where about 40 percent of all new diagnoses of Type 2 Diabetes occur in those whose BMI falls under 22 kilograms per square meter. This “thin-fat” Indian phenotype, characterized by low muscle mass and relatively large amounts of visceral fat, represents a cardiovascular/metabolic risk profile that standard screening tools are structured to fail to detect. Being in the normal weight category does not equate to having good metabolic health.
BMI was created in 1832 for the purposes of describing average values in populations, not individual health, by an actuary (a statistician) who was not a physician. Visceral obesity in individuals with labels like “MONO” may result from metabolic disturbances; since body mass index (BMI), which is used to identify such conditions, cannot quantify amounts of visceral fat, it will continue to be inadequate. As of January 2025, a commission on diabetes and endocrinology published by The Lancet has provided the recommendations of 58 international health care professionals that BMI should no longer be considered an accurate representation of either health or disease at the individual level, recommending waist circumference, waist-to-height ratio, and direct measurements of body fat as alternative measures. This recommendation would seem especially relevant for South Asians because when they have the same BMI as European Americans, they have significantly more visceral fat. (nih)
The 2025 ICMR-INDIAB study (the first, largest national population-based metabolic epidemiological survey to be done in India) surveyed 113,043 participants from each of the 31 states of India. It demonstrated that 43.3% of Indian adults will have Metabolic Obesity Normal Weight (MONO). That percentage far exceeds the global average of 26.78%, as established by meta-analysis internationally; it indicates the specific metabolic vulnerabilities associated with the South Asian Phenotype. In addition, it was also verified that MONO individuals are at an increased risk for Type 2 Diabetes, Coronary Artery Disease, and Chronic Kidney Disease – all three conditions occur without symptoms before normal BMI and apparently normal clinical laboratory studies. As such, the ICMR-INDIAB data represent the best existing population-level evidence about MONO in India.
TyG index cut-off values for men and women (normal weight)
The TyG index, obtained through multiplication of fasting triglycerides by fasting glucose, is being explored as a low-cost marker for identifying ir in normal weight people. A recent article in Nutrition & Diabetes provided cut-off values of 8.82 for males and 8.73 for females to serve as the threshold for diagnosing mono. Individuals who are greater than these values have roughly double the chance of developing T2DM as those classified as metabolically healthy, normal weight. The TyG index has a sensitivity of 84.2% and specificity of 77.6%, as opposed to HOMA-IR, which is dependent on an insulin assay, which may need to be specially ordered.
The MONO (Metabolically Obese Normal Weight) phenotype is present in varying degrees of frequency within different global populations. However, certain racial/ethnic groups exhibit vastly differing frequencies for MONO; for example, MONO appears to be present in much greater numbers of Indians as compared to Chinese populations when comparing those populations based on equivalent BMIs. Studies have shown that South Asians tend to possess significantly lower amounts of lean muscle mass and a disproportionate amount of visceral and ectopic fat relative to Europeans of the same BMI. Additionally, when South Asian individuals are consuming above their energy expenditure requirements, they appear to preferentially accumulate fat in ectopic locations (the liver, pancreas, and viscera), as opposed to accumulating it under the skin. These ectopic fat accumulations contribute to the development of hepatic insulin resistance and pancreatic beta cell dysfunction, in addition to causing chronic systemic inflammation at body weight ranges where such risks would be negligible for European patients. In order to confirm this mechanism in an Indian population of approximately 1,500 normal-weight adults, the ADA’s 2025 Gujarat Phenotype Study was conducted.
The terms above all refer to a similar metabolic state. Although the definitions are slightly different, they all define an individual with a normal Body Mass Index (BMI). However, this individual has characteristics that may be related to obesity. “MONO” and “MONW” are interchangeable terms that have been found in the medical literature. Both terms were used to describe an individual who had a normal weight but exhibited characteristics associated with being obese. In addition, many consumers commonly use the term “skinny fat”. This term was defined as having low amounts of lean muscle mass and a high amount of abdominal fat, which is often referred to as sarcopenic obesity. The term “normal weight obesity” emphasizes the paradox of appearing slender yet having a large amount of body fat. Each of the aforementioned terms utilizes the same diagnostic criteria. These criteria include a normal BMI (18.5 – 24.9 kg/m²) in combination with two or more of the following: increased visceral fat, impaired glucose tolerance/insulin resistance (HOMA-IR>2), elevated TyG index, dyslipidemia, increased fasting blood sugar, and/or hypertension. Individuals from South Asia, and particularly those from India, exhibit the highest prevalence rates of normal weight obesity. This is primarily due to the existence of a “thin-fat” phenotype in these populations.
The best way to make an absolute MONO diagnosis will be with a combination of tests you wouldn’t normally have as part of your typical yearly health check-up at the doctor’s office. Fasting Insulin (which is used to find HOMA-IR — this is the standard method to find out how resistant to insulin you are). TyG Index (this is a proven & low-cost alternative to directly measuring insulin resistance — it calculates the product of triglyceride levels and blood sugar levels; it has been validated by several studies), Body Composition Analysis by using either an Inbody Scan or DEXA (these both measure Visceral Fat Area, Skeletal Muscle Mass, and Total Body Percentage of Fat); Waist-to-Height Ratio (any time your WtHR > .50 is considered to be clinically relevant regardless of your BMI); High Sensitivity CRP Test (this measures your overall level of inflammation in your body.) All of these tests combined provide the ability to identify individuals who suffer from MONO long before their results on Standard Fasting Glucose/HbA1C Panels would ever indicate anything abnormal — which explains why MONO tends to carry such “Diagnostic Invisibility” within routine clinical practice across India.
Yes. MONO can be reversed, especially if detected early. The most well-studied (peer-reviewed) interventions for reversing MONO include:
Resistance training (at least three times per week using progressive loads). This type of training decreases visceral fat and increases the body’s ability to utilize glucose through improvements in insulin sensitivity via an increase in the amount of skeletal muscle. Skeletal muscle is the body’s primary location where glucose is utilized.
Mediterranean-style diets. These types of diets have been shown to decrease HOMA-IR, reduce triglyceride levels, and reduce visceral fat area (VFA) in all clinical trial studies.
Optimization of sleep (7-9 hours). Sleep has been shown to interrupt the visceral fat-cortisol cycle, thereby preventing additional visceral fat from being deposited. Visceral fat accumulation due to cortisol occurs independently of caloric intake.
Stress management. Chronic stress results in the deposition of visceral fat secondary to elevated glucocorticoids regardless of caloric intake.
Caloric restriction plus physical activity has resulted in the reversal of the MONO syndrome – this includes the restoration of normal insulin sensitivity as well as reductions in intra-abdominal adipose tissue and improved beta cell function in several clinical studies.
